ProCE Banner Events

Share

Application of Evolving Evidence in Mantle Cell Lymphoma: Therapeutic Strategies Using BTK Inhibitors

Join us for this engaging, CME-certified live symposium at ASH 2024 on the optimal use of BTK inhibitors in mantle cell lymphoma. Explore expert insights on approved therapies and emerging treatment strategies with BTK inhibitors and participate in discussions with our panel of specialists.

Friday Satellite Symposium on "Application of Evolving Evidence in Mantle Cell Lymphoma: Therapeutic Strategies Using BTK Inhibitors," preceding the 66th ASH Annual Meeting and Exposition. 

Physicians: maximum of 2.25 AMA PRA Category 1 Credits™

Physicians ABIM MOC: maximum of 2.25 Medical Knowledge MOC points

Who Should Attend

This program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with mantle cell lymphoma.

Time and location

Friday, December 06, 2024

11:00 AM - 1:45 PM Pacific Time (PT)

In-person

11:30 AM - 1:45 PM Pacific Time (PT)

Virtual

Manchester Grand Hyatt San Diego
1 Market Place
San Diego, California 92101

Grand Hall D

Faculty
Brad Kahl, MD

Professor of Medicine
Washington University in St Louis
Director, Lymphoma Program
Siteman Cancer Center
St Louis, Missouri

John P. Leonard, MD

Senior Associate Dean for Innovation and Initiatives
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Weill Cornell Medicine/NewYork-Presbyterian
New York, New York

Julie M. Vose, MD, MBA

Payne Presidential Chair
Chief, Division of Hematology/Oncology
University of Nebraska Medical Center
Buffett Cancer Center
Omaha, Nebraska

Agenda

Registration & Lunch: 11:00 AM - 11:30 AM PT
Symposium: 11:30 AM - 1:45 PM PT

  • Welcome and Introduction
  • BTK Inhibitors in MCL: Overview
  • Optimizing Treatment for MCL: Considerations for BTK Inhibitor Therapy
  • Treatment Selection for MCL: Variations in Disease Presentation and Management Decisions Regarding Treatment
  • Audience Question and Answer Session
  • Final Thoughts

Location

Venue Name

Manchester Grand Hyatt San Diego

Address

Manchester Grand Hyatt San Diego
1 Market Place
San Diego, California 92101

Room Name

Grand Hall D

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Mantle cell lymphoma (MCL).

Target Audience
This program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with mantle cell lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply recent data, safety profiles, and expert opinion to the selection of BTK inhibitor based combinations in treatment-naïve mantle cell lymphoma
  • Use recommended, evidence-based approaches to address adverse events associated with BTK inhibitor therapy in patients with B-cell lymphomas
  • Assess patients for challenges to adherence and persistence to prescribed BTK inhibitor regimens in mantle cell lymphoma
  • Evaluate evidence for current and emerging treatment options for patients with relapsed/refractory MCL following treatment with BTK inhibitors in the treatment naïve setting

Accreditation

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by an educational grant from AstraZeneca.

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.